Vaxcyte Net Income Applicable To Common Shares from 2010 to 2024

PCVX Stock  USD 93.98  2.53  2.77%   
Vaxcyte Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss is likely to outpace its year average in 2024. Net Loss is the net income that remains after preferred dividends have been deducted, available to common shareholders. View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-201.1 M
Current Value
-191.1 M
Quarterly Volatility
76 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 66.1 M, Interest Expense of 0.0 or Selling General Administrative of 63.7 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.16. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.
  
Check out the analysis of Vaxcyte Correlation against competitors.
For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Latest Vaxcyte's Net Income Applicable To Common Shares Growth Pattern

Below is the plot of the Net Income Applicable To Common Shares of Vaxcyte over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. Vaxcyte's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.
Net Income Applicable To Common Shares10 Years Trend
Slightly volatile
   Net Income Applicable To Common Shares   
       Timeline  

Vaxcyte Net Income Applicable To Common Shares Regression Statistics

Arithmetic Mean(68,177,212)
Coefficient Of Variation(111.53)
Mean Deviation61,881,216
Median(17,238,000)
Standard Deviation76,035,708
Sample Variance5781.4T
Range206.2M
R-Value(0.84)
Mean Square Error1880.7T
R-Squared0.70
Significance0.0001
Slope(14,204,035)
Total Sum of Squares80940T

Vaxcyte Net Income Applicable To Common Shares History

2024-191.1 M
2023-201.1 M
2022-223.5 M
2021-100.1 M
2020-89.2 M
2019-50.3 M
2018-29.5 M

About Vaxcyte Financial Statements

Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-201.1 M-191.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.